137 related articles for article (PubMed ID: 18940750)
1. Primary ovarian Burkitt lymphoma.
Muñoz Martín AJ; Pérez Fernández R; Viñuela Beneítez MC; Martínez Marín V; Marquéz-Rodas I; Sabin Domínguez P; García Alfonso P
Clin Transl Oncol; 2008 Oct; 10(10):673-5. PubMed ID: 18940750
[TBL] [Abstract][Full Text] [Related]
2. RD-CODOX-M/IVAC with rituximab and intrathecal liposomal cytarabine in adult Burkitt lymphoma and 'unclassifiable' highly aggressive B-cell lymphoma.
Corazzelli G; Frigeri F; Russo F; Frairia C; Arcamone M; Esposito G; De Chiara A; Morelli E; Capobianco G; Becchimanzi C; Volzone F; Saggese M; Marcacci G; De Filippi R; Vitolo U; Pinto A
Br J Haematol; 2012 Jan; 156(2):234-44. PubMed ID: 22098541
[TBL] [Abstract][Full Text] [Related]
3. Primary bilateral ovarian Burkitt's lymphoma in a six-year-old child: report of a rare malignancy.
Mondal SK; Bera H; Mondal S; Samanta TK
J Cancer Res Ther; 2014; 10(3):755-7. PubMed ID: 25313777
[TBL] [Abstract][Full Text] [Related]
4. Chemoimmunotherapy with hyper-CVAD plus rituximab for the treatment of adult Burkitt and Burkitt-type lymphoma or acute lymphoblastic leukemia.
Thomas DA; Faderl S; O'Brien S; Bueso-Ramos C; Cortes J; Garcia-Manero G; Giles FJ; Verstovsek S; Wierda WG; Pierce SA; Shan J; Brandt M; Hagemeister FB; Keating MJ; Cabanillas F; Kantarjian H
Cancer; 2006 Apr; 106(7):1569-80. PubMed ID: 16502413
[TBL] [Abstract][Full Text] [Related]
5. Update of the M. D. Anderson Cancer Center experience with hyper-CVAD and rituximab for the treatment of mantle cell and Burkitt-type lymphomas.
Fayad L; Thomas D; Romaguera J
Clin Lymphoma Myeloma; 2007 Dec; 8 Suppl 2():S57-62. PubMed ID: 18284717
[TBL] [Abstract][Full Text] [Related]
6. Ovarian Burkitt's lymphoma diagnosed by a combination of clinical features, morphology, immunophenotype, and molecular findings and successfully managed with surgery and chemotherapy.
Chishima F; Hayakawa S; Ohta Y; Sugita K; Yamazaki T; Sugitani M; Yamamoto T
Int J Gynecol Cancer; 2006; 16 Suppl 1():337-43. PubMed ID: 16515618
[TBL] [Abstract][Full Text] [Related]
7. Adding rituximab to CODOX-M/IVAC chemotherapy in the treatment of HIV-associated Burkitt lymphoma is safe when used with concurrent combination antiretroviral therapy.
Alwan F; He A; Montoto S; Kassam S; Mee M; Burns F; Edwards S; Wilson A; Tenant-Flowers M; Marcus R; Ardeshna KM; Bower M; Cwynarski K
AIDS; 2015 May; 29(8):903-10. PubMed ID: 25730506
[TBL] [Abstract][Full Text] [Related]
8. 24-year-old female with amenorhea: bilateral primary ovarian Burkitt lymphoma.
Baloglu H; Turken O; Tutuncu L; Kizilkaya E
Gynecol Oncol; 2003 Nov; 91(2):449-51. PubMed ID: 14599883
[TBL] [Abstract][Full Text] [Related]
9. Intensive chemotherapy with cyclophosphamide, doxorubicin, high-dose methotrexate/ifosfamide, etoposide, and high-dose cytarabine (CODOX-M/IVAC) for human immunodeficiency virus-associated Burkitt lymphoma.
Wang ES; Straus DJ; Teruya-Feldstein J; Qin J; Portlock C; Moskowitz C; Goy A; Hedrick E; Zelenetz AD; Noy A
Cancer; 2003 Sep; 98(6):1196-205. PubMed ID: 12973843
[TBL] [Abstract][Full Text] [Related]
10. Burkitt lymphoma of the ovary: a case report and literature review.
Miyazaki N; Kobayashi Y; Nishigaya Y; Momomura M; Matsumoto H; Iwashita M
J Obstet Gynaecol Res; 2013 Aug; 39(8):1363-6. PubMed ID: 23800271
[TBL] [Abstract][Full Text] [Related]
11. Excellent real-world outcomes of adults with Burkitt lymphoma treated with CODOX-M/IVAC plus or minus rituximab.
Zhu KY; Song KW; Connors JM; Leitch H; Barnett MJ; Ramadan K; Slack GW; Abou Mourad Y; Forrest DL; Hogge DE; Nantel SH; Narayanan S; Nevill TJ; Power MM; Sanford DS; Sutherland HJ; Tucker T; Toze CL; Sehn LH; Broady R; Gerrie AS
Br J Haematol; 2018 Jun; 181(6):782-790. PubMed ID: 29741758
[TBL] [Abstract][Full Text] [Related]
12. [Pelvic Burkitt lymphoma mimicking an ovarian tumor].
Magri K; Riethmuller D; Maillet R
J Gynecol Obstet Biol Reprod (Paris); 2006 May; 35(3):280-2. PubMed ID: 16645563
[TBL] [Abstract][Full Text] [Related]
13. Primary ovarian Burkitt's lymphoma: a rare oncological problem in gynaecology: a review of literature.
Stepniak A; Czuczwar P; Szkodziak P; Wozniakowska E; Wozniak S; Paszkowski T
Arch Gynecol Obstet; 2017 Oct; 296(4):653-660. PubMed ID: 28770352
[TBL] [Abstract][Full Text] [Related]
14. Rituximab in combination with CODOX-M/IVAC: a retrospective analysis of 23 cases of non-HIV related B-cell non-Hodgkin lymphoma with proliferation index >95%.
Mohamedbhai SG; Sibson K; Marafioti T; Kayani I; Lowry L; Goldstone AH; Linch DC; Ardeshna KM
Br J Haematol; 2011 Jan; 152(2):175-81. PubMed ID: 21092025
[TBL] [Abstract][Full Text] [Related]
15. Burkitt's lymphoma in a 45-year-old Nigerian woman.
Lawal OO; Ojo OS; Durosinmi MA
Trop Geogr Med; 1990 Jul; 42(3):294-7. PubMed ID: 2293442
[TBL] [Abstract][Full Text] [Related]
16. Obinutuzumab (GA101) compared to rituximab significantly enhances cell death and antibody-dependent cytotoxicity and improves overall survival against CD20(+) rituximab-sensitive/-resistant Burkitt lymphoma (BL) and precursor B-acute lymphoblastic leukaemia (pre-B-ALL): potential targeted therapy in patients with poor risk CD20(+) BL and pre-B-ALL.
Awasthi A; Ayello J; Van de Ven C; Elmacken M; Sabulski A; Barth MJ; Czuczman MS; Islam H; Klein C; Cairo MS
Br J Haematol; 2015 Dec; 171(5):763-75. PubMed ID: 26471982
[TBL] [Abstract][Full Text] [Related]
17. Burkitt's lymphoma presenting as ovarian torsion.
Taylor JS; Frey MK; Fatemi D; Robinson S
Am J Obstet Gynecol; 2012 Aug; 207(2):e4-6. PubMed ID: 22742781
[TBL] [Abstract][Full Text] [Related]
18. Burkitt'S lymphoma mimicking a primary gynecologic tumor.
Lu SC; Shen WL; Cheng YM; Chou CY; Kuo PL
Taiwan J Obstet Gynecol; 2006 Jun; 45(2):162-6. PubMed ID: 17197360
[TBL] [Abstract][Full Text] [Related]
19. [Retrospective study about 20 cases of ovarian Burkitt lymphoma at Yopougon teaching hospital in Côte d'Ivoire].
Kouakou B; Kamara I; Silue AD; Meite N; Botti RP; Tolo-Diebkile A; Sanogo I
Bull Cancer; 2019 Mar; 106(3):275-278. PubMed ID: 30771880
[TBL] [Abstract][Full Text] [Related]
20. Antilymphoma effects of anti-HLA-DR and CD20 monoclonal antibodies (Lym-1 and Rituximab) on human lymphoma cells.
Liu C; DeNardo G; Tobin E; DeNardo S
Cancer Biother Radiopharm; 2004 Oct; 19(5):545-61. PubMed ID: 15650447
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
